A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
2012 · New England Journal of Medicine · 2,004 citations
https://doi.org/10.1056/nejmoa1110557
E
Elliott F. Winton
Emory University(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
120
Papers
6.4K
Citations
29
h-index
66
i10-index
Elliott F. Winton is an academic researcher from Emory University. The author has contributed to research in topics: Myeloproliferative Neoplasms: Diagnosis and Treatment & Chronic Myeloid Leukemia Treatments & Acute Myeloid Leukemia Research. The author has an h-index of 29, co-authored 102 publications.
Papers by this author
worksJanus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
2017 · The Lancet Haematology · 318 citations
https://doi.org/10.1016/s2352-3026(17)30088-1
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
2021 · Nature Medicine · 139 citations
https://doi.org/10.1038/s41591-021-01538-9
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
2013 · Journal of Hematology & Oncology · 94 citations
https://doi.org/10.1186/1756-8722-6-81
Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia
2014 · Leukemia Research Reports · 75 citations
https://doi.org/10.1016/j.lrr.2014.07.002
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat